首页 产品目录 分子砌块 按官能团 NH-唑类 (4R,7S,10S,13R,16S,19R)-13-((1H-吲哚-3-基)甲基)-19-((R)-2-氨基-3-苯基丙酰胺基)-10-(4-氨基丁基)-16-苄基-N-((2R,3R)-1,3-二羟基丁-2-基)-7-((R)-1-羟乙基)-6,9,12,15,18-五氧代-1,2-二硫杂-5,8,11,14,17-五氮杂环二十烷-4-甲酰胺

(4R,7S,10S,13R,16S,19R)-13-((1H-吲哚-3-基)甲基)-19-((R)-2-氨基-3-苯基丙酰胺基)-10-(4-氨基丁基)-16-苄基-N-((2R,3R)-1,3-二羟基丁-2-基)-7-((R)-1-羟乙基)-6,9,12,15,18-五氧代-1,2-二硫杂-5,8,11,14,17-五氮杂环二十烷-4-甲酰胺

(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量

抱歉,暂无牌价信息

晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

83150-76-9

中文名称

(4R,7S,10S,13R,16S,19R)-13-((1H-吲哚-3-基)甲基)-19-((R)-2-氨基-3-苯基丙酰胺基)-10-(4-氨基丁基)-16-苄基-N-((2R,3R)-1,3-二羟基丁-2-基)-7-((R)-1-羟乙基)-6,9,12,15,18-五氧代-1,2-二硫杂-5,8,11,14,17-五氮杂环二十烷-4-甲酰胺

英文名称

(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

别名

DARAMONOL;ctreotide;Ocetreotide, Acetate;L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl-, cyclic (2?7)-disulfide;OXTREOTIDE;[R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2->7)-disulfide;Octreotide acetate;L-cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl) propyl)-cyclic (2->7)-disulfide, (R-(R*,R*))

标准英文名

(4R,7S,10S,13R,16S,19R)-13-((1H-indol-3-yl)methyl)-19-((R)-2-amino-3-phenylpropanamido)-10-(4-aminobutyl)-16-benzyl-N-((2R,3R)-1,3-dihydroxybutan-2-yl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

分子式

C49H66N10O10S2

分子量

1018.44

精确分子量

1018.44

SMILES

O=C([C@@H](NC([C@H](CSSC[C@H](NC([C@](NC([C@@H](NC1=O)CCCCN)=O)([H])[C@H](O)C)=O)C(N[C@H](CO)[C@H](O)C)=O)NC([C@H](N)CC2=CC=CC=C2)=O)=O)CC3=CC=CC=C3)N[C@@H]1CC4=CNC5=CC=CC=C45

标准SMILES

C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=CC=CC=C23)NC(=O)[C@H](CC2C=CC=CC=2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CO)[C@@H](C)O)NC(=O)[C@H](N)CC1C=CC=CC=1

用途

Octreotide acetate is used for: 1. Controlling symptoms in patients with acromegaly who are not adequately managed by surgery or radiotherapy, and reducing plasma levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1); it is also indicated for patients who are not candidates for or refuse surgery, or for those in the interim period before radiotherapy takes effect. 2. Alleviating symptoms associated with functional gastroenteropancreatic (GEP) endocrine tumors, such as carcinoid syndrome, VIPomas, and glucagonomas; however, it is not a curative anticancer agent. 3. Preoperative management of insulinomas to prevent hypoglycemia and maintain normoglycemia. 4. Adjunctive treatment of gastrinomas/Zollinger-Ellison syndrome (typically combined with proton pump inhibitors or H2-receptor antagonists). 5. Management of growth hormone-releasing factor-secreting tumors (with an approximate 50% efficacy rate). 6. Prevention of complications following pancreatic surgery. 7. Emergency treatment, hemostasis, and prevention of rebleeding in patients with esophageal variceal bleeding due to liver cirrhosis, used in combination with endoscopic sclerotherapy or other specific interventions.

InChIKey

DEQANNDTNATYII-OULOTJBUSA-N

安全信息

SureRoute逆合成路线

1.  83150-76-9 逆合成路线 1

ACCZIU451
563-67-7
—
—
ACYORT579
83150-76-9
来源: SureRoute

2.  83150-76-9 逆合成路线 2

—
—
ACYORT579
83150-76-9
来源: SureRoute

3.  83150-76-9 逆合成路线 3

—
—
ACYORT579
83150-76-9
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手